New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289
about
Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sicknessThe development of drugs for treatment of sleeping sickness: a historical reviewA current analysis of chemotherapy strategies for the treatment of human African trypanosomiasisNovel amidines and analogues as promising agents against intracellular parasites: a systematic reviewImaging African trypanosomesIn vivo imaging of trypanosome-brain interactions and development of a rapid screening test for drugs against CNS stage trypanosomiasisThe susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposingCombined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivoPharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasisSafety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasisChemotherapy of second stage human African trypanosomiasis: comparison between the parenteral diamidine DB829 and its oral prodrug DB868 in vervet monkeysEfficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical TrialEfficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical StudiesFacile Synthesis and Preliminary Structure-Activity Analysis of New Sulfonamides Against Trypanosoma bruceiPharmacokinetic comparison to determine the mechanisms underlying the differential efficacies of cationic diamidines against first- and second-stage human African trypanosomiasis.The fourth mammalian molybdenum enzyme mARC: current state of research.In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sicknessDicationic phenyl-2,2'-bichalcophenes and analogues as antiprotozoal agents.Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models.SYNTHESIS OF NOVEL BITHIOPHENE-SUBSTITUTED HETEROCYCLES BEARING CARBONITRILE GROUPS.Trypanocidal furamidine analogues: influence of pyridine nitrogens on trypanocidal activity, transport kinetics, and resistance patterns.Understanding mixed sequence DNA recognition by novel designed compounds: the kinetic and thermodynamic behavior of azabenzimidazole diamidinesA new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei brucei infection is not cross-resistant with diamidines.Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.Antiparasitic chemotherapy: from genomes to mechanisms.A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.Systematic synthetic and biophysical development of mixed sequence DNA binding agents.Trichomonas vaginalis: treatment questions and challenges.Synthesis, antimicrobial, and antiproliferative activities of substituted phenylfuranylnicotinamidines.Novel 4-substituted phenyl-2,2'-bichalcophenes and aza-analogs as antibacterial agents: a structural activity relationship.Luminescent multiplex viability assay for Trypanosoma brucei gambiense.Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasisDrug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.Heterocyclic dications as a new class of telomeric G-quadruplex targeting agentsDesign and synthesis of heterocyclic cations for specific DNA recognition: from AT-rich to mixed-base-pair DNA sequencesDevelopment of novel drugs for human African trypanosomiasis.Drug discovery and human African trypanosomiasis: a disease less neglected?The mammalian molybdenum enzymes of mARC.In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodesIndependence from Kinetoplast DNA maintenance and expression is associated with multidrug resistance in Trypanosoma brucei in vitro.
P2860
Q21144517-FDB69FA2-5249-4F60-BDE0-FB463F4BF811Q21198933-E186B5E8-8393-4A76-86D3-BC378C9D2C5AQ26820381-D9AEA236-137F-4A4C-95CA-6EC896BB2EBEQ26825025-D58592C2-C960-4EF4-84CF-47279429D9B4Q27010326-7F15E52F-5C36-466E-95CB-2823C1A641BEQ27305075-74B4FBFA-DFD3-4F63-98AA-4E9B77CFAD98Q28476644-2433D119-D4D8-401C-98B3-1A0F4589D562Q28479294-285E13D9-E541-439C-9415-464CF5C6F82FQ28481509-07CC4465-3795-4A3F-B92F-34E637D1E97EQ28533660-E7926829-0F41-42D5-8D43-7D2F7A569A93Q28543200-2F7664F3-66ED-4806-95EC-9070F26AAD26Q28550204-3AEE60BC-D5E8-42D3-9A33-38F560883CEAQ28550224-3A0E6FF8-5F4B-4948-9D4D-695F5B010DD8Q33636542-BBCF33D2-F5A2-4867-9DE2-2C4F14735BD3Q33798222-B7BFE88A-A815-4102-BC7F-7ABD448E2D52Q34028677-9B3D84A0-69B0-49A1-8860-F5952D3BB425Q34058294-86D4FDF3-1B1B-4E6D-97BE-1FC2E0BE0DF6Q34725219-39E88E9D-1A9F-4AA1-8503-D1D36912B49FQ34868070-9171F2CD-5504-4AFB-8156-4FE82BA9493DQ34907870-0B1072CA-210B-45B4-A7E1-D9A8B588463FQ34933034-EA284A13-26FA-4216-BFF1-B77A87B8D60CQ35001202-EDFCD43A-AB1D-44F2-B535-B97498883BFCQ35105995-C3BB1E1E-1FC2-43AD-A438-C2B171E75400Q35189546-659DA6F3-8351-4A35-982D-E289701B4CFBQ35238319-BD54E69A-25BA-42B9-BEAD-6250E522ACF2Q35647136-7E46A46B-F5BC-4355-AA33-FF4159F96873Q36229107-A1F910A8-4BD8-48EC-9E98-8B019B962655Q36347999-32C61118-D746-4FE4-AA71-6425E9C6ADDEQ36697144-3623B25E-4472-450F-9AA9-A22046FA1D8DQ36723419-B674CD5C-4626-4780-8812-5A268D54A07EQ37057168-A1DA11C2-A020-441A-8BF4-2F467287152DQ37263574-3E08CA24-6355-4313-854E-993E3D08D097Q37317284-D324BA91-C4DE-46ED-A4AE-353526450479Q37397991-AAD2368A-7FCC-4D14-922A-B65A783964D2Q37701067-E87D4828-29A9-4332-BEBF-B737FFE8BCFFQ37894699-CFE65178-AB87-4888-BF2A-0C0C33C2B725Q38154344-8A55B46E-7734-4FD4-BC6F-1FB09E76AD78Q38271482-7F1DD8ED-2C0E-45EA-B61F-858AF7726E65Q38627137-A0571FFD-97DE-49A9-A550-798B18BC26F5Q38848911-6065FCCB-466C-4A09-AD1E-1F3C685AF7F1
P2860
New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New treatment option for secon ...... ficacy of aza analogs of DB289
@en
New treatment option for secon ...... icacy of aza analogs of DB289.
@nl
type
label
New treatment option for secon ...... ficacy of aza analogs of DB289
@en
New treatment option for secon ...... icacy of aza analogs of DB289.
@nl
prefLabel
New treatment option for secon ...... ficacy of aza analogs of DB289
@en
New treatment option for secon ...... icacy of aza analogs of DB289.
@nl
P2093
P2860
P356
P1476
New treatment option for secon ...... ficacy of aza analogs of DB289
@en
P2093
David W Boykin
James Edwin Hall
Richard R Tidwell
P2860
P304
P356
10.1128/AAC.00225-09
P407
P577
2009-07-20T00:00:00Z